Overview Paricalcitol Injection Phase II Trial Status: Completed Trial end date: 1969-12-31 Target enrollment: Participant gender: Summary The PK and tolerability of paricalcitol after repeated intravenous administration for 2 weeks (total 6 doses at every HD session) are studied in subjects with 2°HPT who are receiving HD 3 times a week for stable chronic renal failure. Phase: Phase 2 Details Lead Sponsor: AbbottTreatments: Ergocalciferols